Mounjaro Lawsuit Updates 2025-2026 Our firm is committed to providing accurate, up-to-date information about lawsuits for side effects potentially caused by the use of Mounjaro
Most episodes were mild to moderate, and the median duration of individual nausea episodes was approximately 8 days
In December 2025, the Trump administration announced the BALANCE Model a new federal program that could expand access to GLP-1s through both Medicare and Medicaid beginning as early as May 2026
Critically, subtherapeutic drug exposure levels correlate with increased relapse rates or graft failure, while supratherapeutic concentrations are linked to a greater risk of severe toxicities and treatment-related mortality (Bartelink et al., 2016)
It uses immunosuppressive chemotherapy to remove the immune cells that produce the anti-receptor antibodies, then reinfuses the patients own stored stem cells to rebuild an immune system that no longer attacks the neuromuscular junction